Page 20 - GP Spring 2024
P. 20

Test your knowledge with some questions.



                                                       Earn 1 CE credit
        To complete the questionnaire use the link:           or scan the QR code:
        https://docs.google.com/forms/d/1e-
        vdMxup9lyoYJzYgZrKct9Df9xWy-
        fz80aHlQZh5iRZo/edit




        Questions from articles
        Please answer 80% of the questions correctly to receive 1 CE credit.
        Questions 1, 2, and 3  are from the article: Oral Manifestations of Long-Term Highly Active Antiretroviral Therapy (HAART)
        pages 4 and 5
        Questions 4 and 5   are from the article: Beyond Substitution Therapy: Exploring the Impact of Suboxone on
        Oral Health pages 15-16 and 17.
        (* Required)


        Question 1
        Which of the following oral findings was found to be most commonly associated with the use of HAART medications? (*1 point)
        ❍ Oral hyperpigmentation
        ❍ Oral ulcerations
        ❍ Oral candidiasis
        ❍ Oral herpes

        Question 2
        The article discussed a study that found that HAART therapy decreases the risk of all these oral manifestations except one; which is the
        exception? (*1 point)
        ❍ Candidiasis
        ❍ Oral herpes
        ❍ Oral hairy leukoplakia
        ❍ Oral hyperpigmentions

        Question 3
        According to the article, hyperpigmentation was commonly found in all of these locations except one; which is the exception? (*1 point)
        ❍ Tongue
        ❍ Gingiva
        ❍ Buccal mucosa
        ❍ Lips

        Question 4
        According to some studies, which of the following is the most common risk factor for caries associated with methadone use? (*1 point)
        ❍ The sugar- content formulation
        ❍ Salivary gland dysfunction
        ❍ It can cause hypersalivation
        ❍ The mechanism of action

        Question 5
        All of the following are true concerning using buprenorphine/naloxone except one, which is the exception? (*1 point)
        ❍ It is use for opioid-replacement
        ❍ Partial agonist at the mu receptor
        ❍ Analgesic plateau at higher doses
        ❍ Sugar containing product









        www.nysagd.org l Spring 2024 l GP 20
   15   16   17   18   19   20   21